Gilead I. Lancaster
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gilead I. Lancaster has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Fabricio Malaguez Webber
Department of Cardiovascular Diseases, University of Miami, FL, USA
3 shared publications - Ashraf Ahmed
Department of Internal Medicine Yale University School of Medicine, Bridgeport Hospital Bridgeport Connecticut USA
2 shared publications Hitender Jain
2 shared publications- Mohammed Elmurtada
Internal Medicine Department, Bridgeport Hospital, Yale New Haven Health, CT, USA
2 shared publications - Rasha Kaddoura
Pharmacy Department, Heart Hospital, Hamad Medical Corporation, Doha, Qatar -
2 shared publications Stuart W. Zarich
Division of Cardiology, Department of Medicine, Yale New Haven Health, Bridgeport Hospital, Bridgeport, Connecticut
2 shared publications
Latest Publications
- Open Access
- 13 June 2024
- Published by Elsevier in Structural Heart
- Vol. 8 (6) , 100327
In-Hospital Outcomes and 30-Day Readmission Rate After Transcatheter and Surgical Aortic Valve Replacement in Liver Cirrhosis: A Contemporary Propensity-Matched Analysis
- 13 June 2024
- Published by Elsevier in Structural Heart
- Vol. 8 (6) , 100327
Open AccessIn-Hospital Outcomes and 30-Day Readmission Rate After Transcatheter and Surgical Aortic Valve Replacement in Liver Cirrhosis: A Contemporary Propensity-Matched Analysis
- Open Access
- 12 April 2024
- Published by ICR Publications LTD in Journal of Heart Valve Disease Innovation
- Vol. 29 (1) , 45-50
Outcomes of Mitral Valve Transcatheter Edge-To-Edge Repair In Patients With Chronic Kidney Disease: A Systematic Review And Meta-Analysis
Background: Transcatheter edge-to-edge repair of the mitral valve (M-TEER) improves outcomes in patients with chronic severe symptomatic mitral valve regurgitation who are at high risk for surgical mitral valve repair or replacement. This systematic review and meta-analysis aimed to describe the outcomes of M-TEER in patients with moderate-to-severe (stage III; Group 1) chronic kidney diseases (CKD) and end-stage kidney disease (stages IV-V; Group 2) in comparison with those with normal kidney function or mild CKD (stages I-II; Group 3). Methods: A systematic literature search of PubMed, Scopus, and Embase was conducted from inception to December 10th, 2023. The odds ratio (OR) with a 95% confidence interval (CI) was pooled using the random-effects model. Results: We screened 6,090 articles of which 40 citations were reviewed in full texts. Eight cohort observational studies met the eligibility criteria. Group 1 versus Group 3: short-term and long-term mortality were significantly higher in Group 1 [(OR 1.73, CI: 1.30-2.29) and (OR 1.78, CI: 1.38-2.29), respectively]. The shock was significantly higher (OR 1.95, CI: 1.45-2.63), and vascular complications were significantly lower (OR 0.51, CI: 0.26-0.99) in Group 1. The incidence of stroke, cardiac tamponade, or conversion to open surgery did not differ between groups [OR 0.87, CI: 0.34-2.23), (OR 1.52, CI: 0.62-2.75), or (OR 0.53, 95% CI: 0.12-2.24), respectively]. Group 2 versus Group 3: long-term mortality was significantly higher in Group 2 (OR 3.56, CI: 2.53-5.02) without a difference in short-term mortality (OR 4.92, CI: 0.91-26.72) or conversion to open surgery (OR 0.92, CI: 0.45-1.91) between groups. Conclusion: In patients who are undergoing M-TEER, impaired kidney function may be associated with increased odds of mortality in comparison with absence or mild kidney impairment.
- 12 April 2024
- Published by ICR Publications LTD in Journal of Heart Valve Disease Innovation
- Vol. 29 (1) , 45-50
Open AccessOutcomes of Mitral Valve Transcatheter Edge-To-Edge Repair In Patients With Chronic Kidney Disease: A Systematic Review And Meta-Analysis
Background: Transcatheter edge-to-edge repair of the mitral valve (M-TEER) improves outcomes in patients with chronic severe symptomatic mitral valve regurgitation who are at high risk for surgical mitral valve repair or replacement. This systematic review and meta-analysis aimed to describe the outcomes of M-TEER in patients with moderate-to-severe (stage III; Group 1) chronic kidney diseases (CKD) and end-stage kidney disease (stages IV-V; Group 2) in comparison with those with normal kidney function or mild CKD (stages I-II; Group 3). Methods: A systematic literature search of PubMed, Scopus, and Embase was conducted from inception to December 10th, 2023. The odds ratio (OR) with a 95% confidence interval (CI) was pooled using the random-effects model. Results: We screened 6,090 articles of which 40 citations were reviewed in full texts. Eight cohort observational studies met the eligibility criteria. Group 1 versus Group 3: short-term and long-term mortality were significantly higher in Group 1 [(OR 1.73, CI: 1.30-2.29) and (OR 1.78, CI: 1.38-2.29), respectively]. The shock was significantly higher (OR 1.95, CI: 1.45-2.63), and vascular complications were significantly lower (OR 0.51, CI: 0.26-0.99) in Group 1. The incidence of stroke, cardiac tamponade, or conversion to open surgery did not differ between groups [OR 0.87, CI: 0.34-2.23), (OR 1.52, CI: 0.62-2.75), or (OR 0.53, 95% CI: 0.12-2.24), respectively]. Group 2 versus Group 3: long-term mortality was significantly higher in Group 2 (OR 3.56, CI: 2.53-5.02) without a difference in short-term mortality (OR 4.92, CI: 0.91-26.72) or conversion to open surgery (OR 0.92, CI: 0.45-1.91) between groups. Conclusion: In patients who are undergoing M-TEER, impaired kidney function may be associated with increased odds of mortality in comparison with absence or mild kidney impairment.
- Open Access
- 12 April 2024
- Published by ICR Publications LTD in Journal of Heart Valve Disease Innovation
- Vol. 29 (1) , 60-70
Management of Cardiogenic Shock in Mitral Valve Diseases: A Review Article
Despite advances in the field of cardiology, cardiogenic shock (CS) remains a management dilemma with a high mortality rate. While most cases of CS are secondary to acute coronary syndrome (ACS), approximately one-fifth can be attributed to delayed mechanical complications of ACS, such as arrhythmia, cardiac tamponade, or valvular heart diseases. The coexistence of CS and mitral valve diseases (MVDs) further complicates clinical presentation, diagnosis, and management strategies. Surgical interventions are considered the gold standard for managing MVDs in the context of CS. However, these patients are often at extreme surgical risk and may not achieve favorable outcomes. Catheter-based interventions have garnered increasing interest, but despite their promising results, most trials have excluded patients in unstable or critical conditions. Pharmacological and mechanical circulatory support provide a bridge to definitive transcatheter or surgical intervention.
- 12 April 2024
- Published by ICR Publications LTD in Journal of Heart Valve Disease Innovation
- Vol. 29 (1) , 60-70
Open AccessManagement of Cardiogenic Shock in Mitral Valve Diseases: A Review Article
Despite advances in the field of cardiology, cardiogenic shock (CS) remains a management dilemma with a high mortality rate. While most cases of CS are secondary to acute coronary syndrome (ACS), approximately one-fifth can be attributed to delayed mechanical complications of ACS, such as arrhythmia, cardiac tamponade, or valvular heart diseases. The coexistence of CS and mitral valve diseases (MVDs) further complicates clinical presentation, diagnosis, and management strategies. Surgical interventions are considered the gold standard for managing MVDs in the context of CS. However, these patients are often at extreme surgical risk and may not achieve favorable outcomes. Catheter-based interventions have garnered increasing interest, but despite their promising results, most trials have excluded patients in unstable or critical conditions. Pharmacological and mechanical circulatory support provide a bridge to definitive transcatheter or surgical intervention.
- 27 June 2017
- Published by ASME International in Journal of Medical Devices
- Vol. 11 (3) , 031001
Continuous, Real-Time, Noninvasive Hemodynamic Cardiac Doppler Monitoring With a Novel Hands-Free Device: A Feasibility Study Compared to Standard Echo
This study sought to determine the feasibility of using noninvasive cardiac hemodynamics (NICHE), a new noninvasive Doppler-based device, to monitor real-time, simultaneous tissue and blood-flow Doppler measurements in a clinical setting, and to obtain preliminary performance data compared to a commercially available system. Doppler-based measurements have been shown to correlate well with invasive hemodynamic data and diastolic function, but their use in clinical applications has been limited by various technical issues. The NICHE device was developed to obtain simultaneous tissue and blood-flow Doppler measurements automatically, in real-time and in a hands-free manner. Thirty participants (ten normal volunteers and 20 patients in a cardiac rehab program) underwent standard echocardiographic/Doppler studies followed immediately by NICHE monitoring. Early diastolic transmitral blood-flow velocity (E) and tissue Doppler myocardial wall velocity during early relaxation (E′) were acquired using a standard echo device; and E/E′ was derived post hoc. NICHE measurements included E, E′, and directly measured instantaneous E/E′. NICHE was successfully used in 28 participants. Measurements of ENICHE ranged from 40 cm/s to over 120 cm/s and correlated well with Eecho (R = 0.93). ranged from 2 to 23 cm/s and correlated well with the averaged (R = 0.91). Directly measured E/ ratios ranged from 3 to 23 and correlated well with derived E/ (R = 0.91). The NICHE device can monitor patients in a hands-free manner and can supply real-time Doppler derived measurements of hemodynamic parameters and diastolic function that correlate well with measurements from standard echo devices.- 27 June 2017
- Published by ASME International in Journal of Medical Devices
- Vol. 11 (3) , 031001
Continuous, Real-Time, Noninvasive Hemodynamic Cardiac Doppler Monitoring With a Novel Hands-Free Device: A Feasibility Study Compared to Standard Echo
This study sought to determine the feasibility of using noninvasive cardiac hemodynamics (NICHE), a new noninvasive Doppler-based device, to monitor real-time, simultaneous tissue and blood-flow Doppler measurements in a clinical setting, and to obtain preliminary performance data compared to a commercially available system. Doppler-based measurements have been shown to correlate well with invasive hemodynamic data and diastolic function, but their use in clinical applications has been limited by various technical issues. The NICHE device was developed to obtain simultaneous tissue and blood-flow Doppler measurements automatically, in real-time and in a hands-free manner. Thirty participants (ten normal volunteers and 20 patients in a cardiac rehab program) underwent standard echocardiographic/Doppler studies followed immediately by NICHE monitoring. Early diastolic transmitral blood-flow velocity (E) and tissue Doppler myocardial wall velocity during early relaxation (E′) were acquired using a standard echo device; and E/E′ was derived post hoc. NICHE measurements included E, E′, and directly measured instantaneous E/E′. NICHE was successfully used in 28 participants. Measurements of ENICHE ranged from 40 cm/s to over 120 cm/s and correlated well with Eecho (R = 0.93). ranged from 2 to 23 cm/s and correlated well with the averaged (R = 0.91). Directly measured E/ ratios ranged from 3 to 23 and correlated well with derived E/ (R = 0.91). The NICHE device can monitor patients in a hands-free manner and can supply real-time Doppler derived measurements of hemodynamic parameters and diastolic function that correlate well with measurements from standard echo devices.- 7 April 2009
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 150 (7) , 490-492
The Expanding Medical and Behavioral Resources with Access to Care for Everyone Health Plan
Healthcare Professionals for Healthcare Reform is a group of physicians and others interested in health care reform who, recognizing the urgent need for change, convened to propose a universal health care plan that builds on the strengths of the U.S. health care system and improves on its coverage, efficiency, and capacity for patient choice. The group proposes a tiered plan, the core of which (Tier 1) would be lifetime, basic, publicly funded coverage for the entire population on the basis of the best evidence about which therapies are considered life saving, life-sustaining, or preventive. Optional coverage (Tier 2) would be funded by private insurance and cover all therapies considered to help with quality of life and functional impairment. Items considered to be luxury or cosmetic (Tier 3) would generally not be covered, as is the case under the current system. The entire system would be overseen by a quasi-governmental, largely independent organization known as “The Board,†which would resemble the Federal Reserve and interact with U.S. Department of Health and Human Services agencies to oversee implementation and coverage. By building on the current health care system while introducing other features and efficiencies, the Expanding Medical and Behavioral Resources with Access to Care for Everyone (EMBRACE) plan for universal health insurance coverage offers several advantages over alternative plans that have been proposed.
- 7 April 2009
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 150 (7) , 490-492
The Expanding Medical and Behavioral Resources with Access to Care for Everyone Health Plan
Healthcare Professionals for Healthcare Reform is a group of physicians and others interested in health care reform who, recognizing the urgent need for change, convened to propose a universal health care plan that builds on the strengths of the U.S. health care system and improves on its coverage, efficiency, and capacity for patient choice. The group proposes a tiered plan, the core of which (Tier 1) would be lifetime, basic, publicly funded coverage for the entire population on the basis of the best evidence about which therapies are considered life saving, life-sustaining, or preventive. Optional coverage (Tier 2) would be funded by private insurance and cover all therapies considered to help with quality of life and functional impairment. Items considered to be luxury or cosmetic (Tier 3) would generally not be covered, as is the case under the current system. The entire system would be overseen by a quasi-governmental, largely independent organization known as “The Board,†which would resemble the Federal Reserve and interact with U.S. Department of Health and Human Services agencies to oversee implementation and coverage. By building on the current health care system while introducing other features and efficiencies, the Expanding Medical and Behavioral Resources with Access to Care for Everyone (EMBRACE) plan for universal health insurance coverage offers several advantages over alternative plans that have been proposed.
- 15 February 2009
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 11 (2) , 105-110
Aspirin resistance: an update.
- 15 February 2009
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 11 (2) , 105-110
Aspirin resistance: an update.
- 5 September 2007
- Published by Wiley in Clinical Cardiology
- Vol. 31 (1) , 11-17
The Role of Aspirin Resistance in the Treatment of Acute Coronary Syndromes
The TIMI Risk Score recognizes prior aspirin use as an independent risk factor for adverse outcomes in subjects presenting with an acute coronary syndrome. The etiology of this increased risk awaits clarification, but prior aspirin use may be associated with altered thrombus composition which is more resistant to current treatment modalities as compared to thrombus formation in subjects without prior aspirin use. Post hoc analysis of acute coronary syndrome trials has shown that prior aspirin users treated with unfractionated heparin are at particularly high risk. The addition of glycoprotein IIb/IIIa receptor inhibitor to unfractionated heparin or substitution of low‐molecular‐weight heparin significantly improves outcomes in prior aspirin users. The prognostic significance of prior aspirin use in acute coronary syndromes has important implications not only in clinical practice, but also in the design and interpretation of clinical trials. Copyright
- 5 September 2007
- Published by Wiley in Clinical Cardiology
- Vol. 31 (1) , 11-17
The Role of Aspirin Resistance in the Treatment of Acute Coronary Syndromes
The TIMI Risk Score recognizes prior aspirin use as an independent risk factor for adverse outcomes in subjects presenting with an acute coronary syndrome. The etiology of this increased risk awaits clarification, but prior aspirin use may be associated with altered thrombus composition which is more resistant to current treatment modalities as compared to thrombus formation in subjects without prior aspirin use. Post hoc analysis of acute coronary syndrome trials has shown that prior aspirin users treated with unfractionated heparin are at particularly high risk. The addition of glycoprotein IIb/IIIa receptor inhibitor to unfractionated heparin or substitution of low‐molecular‐weight heparin significantly improves outcomes in prior aspirin users. The prognostic significance of prior aspirin use in acute coronary syndromes has important implications not only in clinical practice, but also in the design and interpretation of clinical trials. Copyright
- 1 September 2001
- Published by Elsevier in International Journal of Cardiology
- Vol. 80 (2-3) , 201-207
Prior aspirin use in unstable angina predisposes to higher risk: the aspirin paradox
- 1 September 2001
- Published by Elsevier in International Journal of Cardiology
- Vol. 80 (2-3) , 201-207
Prior aspirin use in unstable angina predisposes to higher risk: the aspirin paradox
- 4 February 1993
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 328 (5) , 358
Air-Bag-Associated Rupture of the Right Atrium
We recently encountered an unusual complication associated with the deployment of an automobile air bag.
- 4 February 1993
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 328 (5) , 358
Air-Bag-Associated Rupture of the Right Atrium
We recently encountered an unusual complication associated with the deployment of an automobile air bag.